ArticleVeterinary world2017
Mycotoxin binders potential on histological of ovary mice exposed by zearalenone.
Article in Veterinary world, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.
- Pooled it
- Mitigation of mycotoxin residues and activation of endogenous stem cells in broiler chickens using a toxin binder: Implications for meat safety and performance enhancement.Veterinary world · 2025Article
- Investigation of a multicomponent mycotoxin detoxifying agent for aflatoxin B1 and ochratoxin A-induced blood profile in broiler chickens.Veterinary world · 2024Article
- Mycotoxin binder for immune and intestinal histopathology ameliorations against Newcastle disease in vaccinated broilers.F1000Research · 2024Article
- The improvement of eggs quality of Mojosari duck (Veterinary world · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study was conducted to examine the potential of mycotoxin binder in ceasing zearalenone (ZEN) effect on mice reproduction. ZEN mycotoxin can induce reactive oxygen species that may cause damage and cell death. ZEN is estrogenic so that it may affect the reproductive organs failure. MATERIALS AND
methodsMycotoxin binder administration to female mice exposed to ZEN was aimed to count the number of primary follicles, secondary follicles, tertiary follicles, de Graaf's follicles, and the corpus luteum (CL). Negative control group (C) was not exposed to ZEN and without the administration of mycotoxin binders, while positive control group (C+) was exposed to 0.1 mg/mouse/day ZEN and without the provision of mycotoxin binders. Treatment groups (T1, T2, T3) were exposed to 0.1 mg/mouse/day ZEN and mycotoxin binders 0.5; 1; 2 mg/BW/day.
resultsZEN and mycotoxin binders administration was conducted for 10 days. The number of primary follicles, secondary, tertiary, de Graaf's follicles and CL in negative control (C-) was 14.2±1.36, 11.2±0.28, 6.5±0.53, 7.5±0.74, and 2.3±0.35. The number in positive control (C+) group was as follows 7.1±0.12, 3.7±1.17, 3.8±1.21, 1.5±0.62, and 2.3±0.34. Results in treatment 1 (T1) were as follows 6.2±0.16, 5.2±0.16, 3.6±0.16, 2.6±0.19, and 2.6±0.10; in treatment 2 (T2) 7.8±0.28, 5.8±0.53, 3.7±0.26, 2.7±0.26, and 2.5±0.10; and in treatment 3 (T3) 8.4±0.34, 8.4±0.34, 4.6±0.34, 4.5±1.01, and 3.4±0.23.
conclusionThe number of follicles and CL more in line with increasing doses of mycotoxin binders. Required more than 2 mg/mouse/day mycotoxin binders to inhibit the effects of ZEN so that its can maintain the number of primary follicle, secondary follicle, tertiary follicle, the de Graaf's follicle, and the number of CL in the ovary of ZEN-exposed female mice (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.